c FKS mutant Candida isolates were recovered from 24% (6/25) of abdominal candidiasis patients exposed to echinocandin. Candida glabrata (29%) and Candida albicans (14%) mutants were identified. Multidrug-resistant bacteria were recovered from 83% of FKS mutant infections. Mutations were associated with prolonged echinocandin exposure (P ‫؍‬ 0.01), breakthrough infections (P ‫؍‬ 0.03), and therapeutic failures despite source control interventions (100%). Abdominal candidiasis is a hidden reservoir for the emergence of echinocandin-resistant Candida.
chinocandin antifungals are front-line therapy for invasive candidiasis (1) . Echinocandin resistance has emerged with increased use of these agents (2, 3) . Resistance is mediated by point mutations within hot spots of FKS genes, which encode the echinocandin target enzyme ␤-1,3-D-glucan synthase. In studies from our center and others, prior echinocandin exposure was the major risk factor for emergence of FKS mutant Candida (2-4). The phenomenon is most common for Candida glabrata, a species that is unique for its haploid rather than diploid genome. We demonstrated that C. glabrata FKS mutations were predictive of echinocandin therapeutic failure among patients with invasive candidiasis (2) . To date, the overwhelming majority of patients reported to be infected with echinocandin-resistant Candida have candidemia (2-4). Abdominal candidiasis is at least as common as candidemia (5), but the incidence and clinical impact of echinocandin resistance are unknown. In the present study, we tested the hypothesis that FKS mutant Candida isolates are common causes of abdominal candidiasis among patients who have received an echinocandin previously.
Patients with abdominal candidiasis and Ն3 days of prior echinocandin exposure were identified at the University of Pittsburgh Medical Center, a tertiary referral center that specializes in critical care medicine and solid-organ transplantation. Abdominal candidiasis was defined by a Candida-positive culture obtained from an intra-abdominal site by surgery or sterile procedure. Patients must have exhibited at least one of the following: fever (temperature of Ն38°C), hypotension (systolic blood pressure of Յ90 mm Hg or a decrease of Ͼ30 mm Hg from the baseline), local signs and symptoms of inflammation, and/or radiologic findings that suggested abdominal candidiasis. Patients with Candida organisms isolated exclusively from indwelling drains or catheters were excluded.
Candida isolates collected at the onset of abdominal candidiasis were selected from our biorepository. Echinocandin MICs were determined in duplicate by Sensititre YeastOne (Trek Diagnostics), which is the echinocandin susceptibility testing method used most commonly in clinical microbiology laboratories (6) . YeastOne assays may limit the interlaboratory variability in caspofungin MICs reported with the CLSI broth microdilution method (6, 7) . We previously demonstrated a trend toward improved identification of FKS mutant C. glabrata isolates with YeastOne (8, 9) . Candida krusei ATCC 6258 and Candida parapsilosis ATCC 22019 were used as quality controls. MICs were interpreted according to CLSI susceptibility breakpoints (10); intermediate MICs were considered resistant. Multidrug-resistant (MDR) bacteria were defined by nonsusceptibility to at least three antimicrobial drug classes (11) . Hot spots 1 and 2 of FKS1 (all species) and FKS2 (C. glabrata only) were amplified using PCR (2, 8) .
Echinocandin therapeutic failure was defined as breakthrough abdominal candidiasis occurring while the patient had been receiving an echinocandin for Ն3 days or nonbreakthrough disease that failed to respond to an echinocandin and source control interventions (2, 12) . In the latter scenario, failure was determined in accordance with consensus definitions for outcomes of antifungal therapy at 14 days (13) . Comparisons between groups were made by Wilcoxon rank sum tests for continuous variables and chi-square or Fisher's exact tests for categorical variables. Significance was set at P values of Յ0.05 (two tailed).
Twenty-five patients with abdominal candidiasis who received an echinocandin for a median of 42 days (range, 4 to 438 days) were included (Table 1) . Forty percent (10/25) of patients were men; the median age was 54 years (range, 23 to 73 years). All patients had underlying gastrointestinal (GI) diseases, and 92% (23/25) had undergone GI surgery within 30 days preceding the onset of abdominal candidiasis; 44% were solid-organ transplant recipients (multivisceral, 4 patients; small bowel, 4 patients; kidney, 1 patient; liver, 1 patient; and kidney-liver, 1 patient). Disease manifestations included abdominal abscesses (n ϭ 13), peritonitis (n ϭ 8), both abscesses and peritonitis (n ϭ 2), and cholangitis or cholangitis plus peritonitis (n ϭ 1 each). In one patient, a blood culture was also positive for the same Candida species. Forty percent (10/25) of abdominal candidiasis cases were echinocandin breakthrough infections, which occurred during caspofungin (n ϭ 9) or micafungin (n ϭ 1) therapy.
Twenty-seven Candida isolates were recovered from the 25 pa-tients. C. glabrata (n ϭ 17) was the most common, followed by C. albicans (n ϭ 7), Candida tropicalis (n ϭ 2), and C. krusei (n ϭ 1). Two patients had mixed Candida infections (C. albicans-C. glabrata and C. glabrata-C. tropicalis). Eleven Candida isolates were recovered from the 10 echinocandin breakthrough infec-
and C. krusei [n ϭ 1]). One patient had breakthrough infections with both C. glabrata and C. tropicalis. The median anidulafungin, caspofungin, and micafungin MICs were 0.03 g/ml (range, 0.015 to 4 g/ml), 0.12 g/ml (range, 0.06 to 16 g/ml), and 0.03 g/ml (range, 0.008 to 4 g/ml), respectively. The corresponding rates of resistance were 22% (6/27), 30% (8/27), and 19% (5/27), respectively; 19% (5/27) of isolates were resistant to all 3 agents. Twentyfour percent (6/25) of patients were infected with FKS mutant Candida. Mutations were identified in 22% (6/27) of isolates, including 29% (5/17) of C. glabrata and 14% (1/7) of C. albicans isolates. Median duration of prior echinocandin exposure was longer among patients infected with FKS mutant isolates than in those infected with the wild type (119 versus 27 days; P ϭ 0.01). Forty-five percent (5/11) of echinocandin breakthrough isolates were FKS mutants, compared to 6% (1/16) of nonbreakthrough isolates (P ϭ 0.03). All 5 isolates resistant to each echinocandin were FKS mutants. The same FKS mutant C. glabrata isolate was recovered from intra-abdominal and blood cultures in the patient with abdominal candidiasis and candidemia. Concomitant bacterial pathogens were recovered from 76% (19/25) of patients, including each of the patients infected with FKS mutant Candida. Enterococcus spp. were most common (63% [12/19] patients). Abdominal cultures revealed MDR bacteria in 64% (16/25) of patients. Organisms included vancomycin-resistant Enterococcus (VRE; n ϭ 10), MDR Enterobacter spp. (n ϭ 3), extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli (n ϭ 1), ESBL-producing Klebsiella pneumoniae (n ϭ 1), Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (n ϭ 1), MDR Acinetobacter baumannii (n ϭ 1), and MDR E. coli (n ϭ 1). MDR bacteria were recovered from 83% (5/6) of patients infected with FKS mutant Candida.
Echinocandin therapy failed in 52% (13/25) of patients. Therapeutic failures included the 10 breakthrough infections and 3 nonbreakthrough infections that were treated with an echinocan- din and a source control. Echinocandin failure occurred in 100% (6/6) of patients infected with FKS mutant Candida. Seven patients who had nonbreakthrough abdominal candidiasis due to wild-type FKS Candida were treated with an echinocandin and source control; the cure rate was 71% (5/7). In comparison, the abdominal candidiasis cure rates were 67% (6/9) among patients who were treated with fluconazole (including 57% [4/7] of patients treated with a concomitant source control and 100% [2/2] of patients treated with fluconazole alone). This is the first study of echinocandin-resistant candidiasis consisting exclusively of patients with infections other than candidemia. Echinocandin resistance during abdominal candidiasis shared many features previously reported for bloodstream infections, including a predominance of C. glabrata (2) (3) (4) . Indeed, the incidence of FKS mutant C. glabrata was virtually identical to those observed in patients with candidemia and prior echinocandin exposure (29% and 32%, respectively) (2, 8) . As in candidemia, FKS mutations were detected in the setting of extensive prior echinocandin usage (ranging from 28 to 438 days). Moreover, mutations were associated with poor responses to echinocandin therapy, manifested as breakthrough abdominal candidiasis or treatment failures despite concomitant source control. At our center and many others, Candida isolates recovered from nonblood sites are not tested routinely for echinocandin susceptibility. Since blood cultures have poor sensitivity for detecting abdominal candidiasis (14) , most of the echinocandin-resistant isolates in this study were identified retrospectively rather than at the time of infection. In one patient, abdominal candidiasis was the source of FKS mutant C. glabrata candidemia. Therefore, our experience suggests that abdominal candidiasis is a hidden reservoir of echinocandin resistance. In an era of widespread echinocandin use, it is plausible that FKS mutations are also selected at other unrecognized reservoirs. A limitation of this study is that the overall rate of FKS mutations during abdominal candidiasis at our center is unknown. Prospective surveillance studies of echinocandin resistance among Candida isolates recovered from abdominal and other, nonblood sites are warranted.
Our most ominous finding was that FKS mutant Candida isolates were almost always recovered with MDR bacteria. Most cases of abdominal candidiasis are complicated by bacterial coinfections, which are typically due to enteric organisms. The emergence of abdominal infections caused by mixtures of antimicrobial-resistant bacteria and fungi reflects the complexity of patients' underlying medical conditions, shared risk factors, and extensive antibiotic and antifungal usage. Abdominal candidiasis constitutes a spectrum of diseases that typically present as abscesses, cholangitis, or peritonitis (15) . Echinocandin pharmacokinetics-pharmacodynamics during abdominal candidiasis have not been evaluated systematically. Data on penetration into intra-abdominal abscesses are absent. Case reports described caspofungin and micafungin concentrations within bile and ascites to be 30% and 15% of serum, respectively (16, 17) . In animal studies of caspofungin disposition, 35% of a single dose was present within liver parenchyma after 24 h; however, elimination occurred slowly, with 14.2 and 2.8% of the dose still present at days 5 and 12, respectively (18) . The terminal half-life of caspofungin is prolonged when serum and tissue concentrations are comodeled, compared to the half-life in serum alone, supporting a model in which abdominal organs are reservoirs for sustained drug release (19) . It is likely that Candida FKS mutations emerged within the abdominal cavity, biliary tree, or abscesses in the face of prolonged subinhibitory echinocandin concentrations.
Source control is a key element of treatment for abdominal candidiasis, but surgery alone is inferior to combined surgicalantifungal approaches. If adequate source control is achieved, our data indicate that echinocandins can be used successfully against nonbreakthrough abdominal candidiasis due to FKS wild-type isolates. In cases of echinocandin breakthrough abdominal candidiasis, however, our experience suggests that alternative agents are more-judicious options. The challenges of treating echinocandinresistant abdominal candidiasis, particularly when complicated by MDR bacterial coinfection, attest to the importance of rational antimicrobial stewardship policies and other preventive strategies. Studies are needed to better define the epidemiology and clinical aspects of abdominal candidiasis, which is understudied and poorly understood compared to candidemia.
